Product logins

Find logins to all Clarivate products below.


Polycythemia Vera | Treatment Algorithms: Claims Data Analysis | US | 2020

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by the line of therapy in newly diagnosed polycythemia vera patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PV patients?
  • How has ruxolitinib (Jakafi) been integrated into the treatment algorithm and what is its source of business?
  • What percentage of PV patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after the diagnosis?
  • What percentage of PV patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Bristol Myers Squibb, Incyte, Roche, Merck 

Key drugs: Hydroxyurea, ruxolitinib (Jakafi), interferons, antiplatelet therapies

Related Market Assessment Reports

Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Disorder (US)
Bipolar disorder (BPD) is a chronic condition characterized by recurrent episodes of aberrant mood, with patients experiencing manic, depressive, or mixed symptoms between periods of stable mood…
Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulins remain the…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Migraine (US)
Episodic and chronic migraines are often disabling and reduce patients’ quality of life. Despite triptans’ dominance in the treatment algorithm, many patients respond inadequately, cannot…
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…